Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KPRX

Kiora Pharmaceuticals Inc

Feb 12 • 12:35PM ET

2.09

-0.06 -2.57 %

Healthcare • Biotechnology • USA • NASD

Peers: ARWR RGEN EYPT OCUL CLSD ALDX PRQR IRD VSTM PULM

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	8.72%	Shs Outstand	3.43M	Perf Week	-1.65%
Market Cap	7.67M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	0.00%	Shs Float	3.36M	Perf Month	-4.79%
Enterprise Value	-11.31M	PEG	-	EPS next Q	-0.67	Inst Own	35.07%	Short Float	0.40%	Perf Quarter	-8.95%
Income	-8.54M	P/S	-	EPS this Y	-296.55%	Inst Trans	-8.12%	Short Ratio	0.25	Perf Half Y	-16.27%
Sales	0.00M	P/B	0.32	EPS next Y	-30.41%	ROA	-24.99%	Short Interest	0.01M	Perf YTD	5.84%
Book/sh	6.53	P/C	0.40	EPS next 5Y	-	ROE	-32.58%	52W High	4.18 -50.12%	Perf Year	-40.26%
Cash/sh	5.27	P/FCF	-	EPS past 3/5Y	- -	ROIC	-37.70%	52W Low	1.76 18.16%	Perf 3Y	-96.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 42.93%	Gross Margin	-	Volatility	4.96% 5.59%	Perf 5Y	-99.92%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-463.97%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	8.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	44.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.79	EPS Q/Q	100.77%	SMA20	-4.91%	Beta	-0.81	Target Price	12.00
Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-2.04%	Rel Volume	1.77	Prev Close	2.14
Employees	12	LT Debt/Eq	0.01	Earnings	Nov 07 BMO	SMA200	-19.78%	Avg Volume	54.15K	Price	2.09
IPO	Feb 13, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	101.36% -100.00%	Trades		Volume	48,040	Change	-2.57%

Jan-27-26 07:00AM	Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Dec-01-25 06:45AM	Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds (Newsfile)
Nov-07-25 06:00AM	Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Oct-30-25 09:00AM	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders (PR Newswire)
Oct-15-25 07:00AM	Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 (Newsfile)
07:00AM	Loading…
Sep-04-25 07:00AM	Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Aug-08-25 07:00AM	Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases (Newsfile)
Aug-07-25 07:00AM	Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Newsfile)
Aug-01-25 11:51AM	Vicarious Surgical names Stephen From as next CEO (MedTech Dive)
Jul-31-25 04:30PM	Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer (Business Wire)
Jul-22-25 08:55AM	Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease (Newsfile)
Jul-16-25 12:00PM	Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +5.00%
Jun-03-25 07:00AM	Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia (Newsfile) +36.84%
May-09-25 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Newsfile)
May-05-25 07:00AM	Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Newsfile)
07:00AM	Loading…
Apr-04-25 07:00AM	Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference (Newsfile) -7.31%
Mar-25-25 07:00AM	Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 (Newsfile) -5.00%
Mar-12-25 07:00AM	Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting (Newsfile)
Feb-13-25 07:00AM	Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 (Newsfile)
Feb-11-25 06:45AM	Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema (Newsfile) -9.44%
Nov-08-24 07:00AM	Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies (Newsfile)
Oct-30-24 07:28AM	Kiora Pharmaceuticals Gains Approval for Phase 2 Trial (TipRanks)
Oct-29-24 06:45AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa (Newsfile)
Sep-25-24 09:55AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Aug-09-24 02:53PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies (Newsfile)
Aug-06-24 07:03AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
Jul-30-24 06:45AM	Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies (Newsfile)
Jul-10-24 07:00AM	Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation (Newsfile)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
06:45AM	Loading…
Jun-25-24 06:45AM	Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile)
Jun-18-24 09:40AM	Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? (Zacks)
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile) -6.36%
May-20-24 07:00AM	Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences (Newsfile)
May-10-24 01:54PM	KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease (Newsfile)
May-08-24 07:00AM	Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference (Newsfile)
May-06-24 07:00AM	Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa (Newsfile)
Apr-11-24 07:00AM	Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study (Newsfile)
Apr-05-24 07:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Mar-28-24 06:45AM	Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting (Newsfile) +14.41%
Mar-25-24 07:00AM	Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases (Newsfile)
Mar-08-24 07:00AM	Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye (Newsfile)
Feb-01-24 08:14AM	Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today? (InvestorPlace) +53.87%
Jan-31-24 06:40PM	Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million (Newsfile) -6.20%
05:15PM	Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties (Newsfile)
Nov-17-23 01:54PM	Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301 (News Direct)
Nov-09-23 07:18AM	Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa (Newsfile)
Nov-04-23 12:15PM	AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa (Newsfile)
Oct-16-23 07:00AM	Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference (Newsfile) -5.30%
Oct-03-23 07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa (Newsfile)
Sep-21-23 07:00AM	Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years (Newsfile)
Sep-18-23 07:00AM	Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa (Newsfile)
Sep-14-23 07:01AM	Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa (Newsfile)
Sep-01-23 07:00AM	Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 (Newsfile)
Aug-29-23 01:43PM	Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases (Newsfile)
Aug-23-23 07:33PM	Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis (GuruFocus.com) +22.55% -16.80%
07:00AM	Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis (Newsfile)
Aug-22-23 01:06PM	Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program (Newsfile)
Aug-16-23 07:00AM	Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (Newsfile)
Aug-08-23 07:00AM	Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress (Newsfile)
Aug-03-23 07:00AM	Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment (Newsfile)
Aug-01-23 07:00AM	Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors (Newsfile)
Jul-05-23 07:00AM	Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease (Newsfile)
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.57%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire) -7.68%
Jun-15-23 07:00AM	Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 (Newsfile) +5.49%
Jun-14-23 08:00AM	Kiora Pharmaceuticals to Present at Upcoming Investor Conferences (Newsfile)
Jun-06-23 04:30PM	Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile) -7.53%
Jun-02-23 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering (Newsfile) -49.55%
May-09-23 07:00AM	Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments (Newsfile)
May-01-23 07:00AM	Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting (Newsfile) -10.36%
Apr-27-23 02:55PM	Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind (Newsfile) +8.90%
Apr-26-23 07:00AM	Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial Defects (Newsfile) +6.98%
Apr-21-23 07:00AM	Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board (Newsfile) +14.49%
Apr-17-23 07:00AM	Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Mar-30-23 07:00AM	Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting (Newsfile)
Mar-23-23 07:00AM	Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress (Newsfile) -9.37%
Mar-10-23 07:00AM	Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting (Newsfile)
Feb-09-23 12:00PM	Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update (Zacks)
Feb-07-23 08:00AM	Kioras stock rallies as eye drop treatment moves into mid-stage clinical trial (MarketWatch) +38.72%
07:00AM	Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases (Newsfile)
Feb-03-23 07:00AM	Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital (Newsfile)
Jan-09-23 07:00AM	Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website (Newsfile)
Jan-03-23 07:01AM	Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023 (Newsfile)
Dec-14-22 08:19AM	Stonegate Healthcare Reviews Retinitis Pigmentosa (Newsfile)
Nov-18-22 08:30AM	Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants (Newsfile) -35.85%
Nov-17-22 06:45AM	Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa (Newsfile)
Nov-09-22 06:45AM	Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End (Newsfile) -5.76%
Oct-31-22 08:01AM	KOL Webinar on Genetic Blindness Points to Promise of Kioras Pioneering Solution--Clinical Data in Q1 (News Direct)
Oct-17-22 08:00AM	Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease (Newsfile)
Oct-13-22 06:45AM	Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (Newsfile)
Sep-28-22 11:44AM	Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D. (Newsfile) +6.06%
Sep-26-22 06:45AM	Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split (Newsfile) -10.05%
Sep-13-22 06:45AM	Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance (Newsfile) +21.00%
Aug-15-22 06:30AM	KPRX: What a difference a year makes! (Zacks Small Cap Research)
Aug-12-22 06:45AM	Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results (Newsfile) -10.71%
Jul-28-22 06:45AM	Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics (Newsfile)
Jul-26-22 04:38PM	Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option (Newsfile)
Jul-22-22 08:30AM	Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering (Newsfile) -39.76%

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

FLUX Flux Power Holdings inc daily Stock Chart

Peers: TSLA ENPH PLUG BE AMD BLDP JKS ENS FCEL NUV

| Held by: FORH VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	20.98%	Shs Outstand	21.34M	Perf Week	25.00%
Market Cap	28.81M	Forward P/E	135.00	EPS next Y	0.01	Insider Trans	0.00%	Shs Float	16.86M	Perf Month	-10.00%
Enterprise Value	38.40M	PEG	-	EPS next Q	-0.07	Inst Own	38.14%	Short Float	2.38%	Perf Quarter	-43.51%
Income	-7.57M	P/S	0.45	EPS this Y	40.00%	Inst Trans	0.97%	Short Ratio	1.41	Perf Half Y	-19.64%
Sales	63.48M	P/B	-	EPS next Y	104.17%	ROA	-25.10%	Short Interest	0.40M	Perf YTD	6.30%
Book/sh	-0.20	P/C	18.12	EPS next 5Y	-	ROE	-1582.76%	52W High	7.55 -82.12%	Perf Year	-15.62%
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	26.64% 32.27%	ROIC	-	52W Low	1.06 27.36%	Perf 3Y	-80.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	16.21% 31.58%	Gross Margin	30.38%	Volatility	15.77% 9.32%	Perf 5Y	-91.76%
Dividend TTM	-	EV/Sales	0.60	EPS Y/Y TTM	5.01%	Oper. Margin	-9.44%	ATR (14)	0.14	Perf 10Y	-62.50%
Dividend Ex-Date	-	Quick Ratio	0.35	Sales Y/Y TTM	2.14%	Profit Margin	-11.92%	RSI (14)	47.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.84	EPS Q/Q	-52.20%	SMA20	-1.85%	Beta	1.57	Target Price	5.67
Payout	-	Debt/Eq	-	Sales Q/Q	-18.29%	SMA50	-6.42%	Rel Volume	0.66	Prev Close	1.41
Employees	101	LT Debt/Eq	-	Earnings	Feb 12 AMC	SMA200	-37.43%	Avg Volume	284.69K	Price	1.35
IPO	Dec 07, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-86.67% -7.83%	Trades		Volume	93,028	Change	-4.26%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	ROTH MKM	Buy	$10
Feb-04-21	Initiated	Maxim Group	Buy	$30
Oct-12-20	Initiated	ROTH Capital	Buy	$13

Feb-11-26 07:38AM	What To Expect From Flux Power Holdings Inc (FLUX) Q2 2026 Earnings (GuruFocus.com) +9.30%
Feb-05-26 08:31AM	Flux Power to Host Fiscal Second Quarter 2026 Financial Results Conference Call on February 12, 2026 (GlobeNewswire)
Dec-29-25 01:05PM	Is Plug Power's $700M Revenue Target for 2025 Within Reach? (Zacks) -5.71%
Dec-18-25 11:39AM	Solid Electrolyzer Demand Drives Plug Power: Will the Momentum Last? (Zacks)
Dec-16-25 08:31AM	Flux Power Secures Over $3.6 Million Additional eGSE Orders (GlobeNewswire) +5.15%
09:14AM	Loading…
Dec-15-25 09:14AM	Plug Power Surges 77.1% in 6 Months: Should You Buy the Stock or Wait? (Zacks) -11.11%
Dec-09-25 12:05PM	Plug Power Remains Plagued by Margin Woes: Can It Buck the Trend? (Zacks)
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-03-25 08:34AM	FLUX Power to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference (GlobeNewswire) +7.19%
Dec-02-25 10:24AM	Will Softening Equipment Demand Limit Plug Power's Growth Potential? (Zacks)
Nov-26-25 10:56AM	Plug Power vs. Flux Power: Which Clean Energy Stock Has the Edge? (Zacks) +7.74%
Nov-20-25 08:31AM	Flux Power Awarded Patent for Advanced Battery State of Health Technology (GlobeNewswire)
Nov-19-25 10:42AM	Plug Power Undertakes Cost Measures: Can It Overcome Rising Losses? (Zacks) -5.99%
Nov-14-25 12:01AM	Flux Power Holdings Inc (FLUX) Q1 2026 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -16.36%
Nov-13-25 05:35PM	Flux Power Holdings, Inc. (FLUX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.17%
04:05PM	Loading…
04:05PM	Flux Power Reports Fiscal Year 2026 First Quarter Financial Results (GlobeNewswire)
09:40AM	Are Computer and Technology Stocks Lagging Flux Power (FLUX) This Year? (Zacks)
Nov-12-25 07:35AM	Flux Power Holdings Inc (FLUX) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-11-25 12:14PM	monday.com Q3 Earnings & Revenues Surpass Estimates, Both Increase Y/Y (Zacks)
10:35AM	DHI Group Q3 Earnings Beat Estimates, Revenues Rise Y/Y (Zacks)
09:06AM	PLUG's Q3 Equipment Revenues Decline Y/Y: What's the Reason Behind It? (Zacks)
08:31AM	Flux Power Receives UL EE Listing Across Full Material Handling Portfolio and UL 1973 for 80V GSE Energy Solutions (GlobeNewswire)
Nov-06-25 11:59AM	Fortinet Q3 Earnings & Revenues Surpass Estimates, Both Increase Y/Y (Zacks)
08:31AM	Flux Power Secures $2.4 Million in Repeat Orders from Major Food & Beverage and Manufacturing Customer (GlobeNewswire)
Nov-05-25 12:33PM	Can Solid Electrolyzer Demand Drive Plug Power's Q3 Sales? (Zacks) +7.66%
09:15AM	One Stop Systems, Inc. (OSS) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-03-25 04:05PM	Flux Power to Host Fiscal First Quarter 2026 Financial Results Conference Call on November 13, 2025 (GlobeNewswire) +12.24% -16.54%
Oct-31-25 08:00AM	Flux Power Announces Pricing of $9.6 Million Underwritten Public Offering (GlobeNewswire) -35.25%
Oct-28-25 09:30AM	Halper Sadeh LLC Encourages Flux Power Holdings, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire) -21.94%
Oct-24-25 09:40AM	Is Flux Power (FLUX) Stock Outpacing Its Computer and Technology Peers This Year? (Zacks) -7.11%
11:20AM	Loading…
Oct-22-25 11:20AM	Can Plug Power's Equipment Recovery be a Driver for Long-Term Growth? (Zacks) +7.59%
08:50AM	Zacks.com featured highlights include Flux Power, Aura Minerals, Arcturus Therapeutics and Sterling Infrastructure (Zacks)
Oct-21-25 09:07AM	4 Stocks With Recent Price Strength to Maximize Your Gains (Zacks) +6.72%
Oct-20-25 05:15PM	Flux Power Regains Compliance with Nasdaq's Continued Listing Requirements (GlobeNewswire) +8.01%
Oct-17-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Flux Power Holdings, Inc. (FLUX) is a Great Choice (Zacks)
Oct-10-25 10:00AM	Can Plug Power's Cost Discipline Deliver Long-Term Margin Growth? (Zacks)
Oct-09-25 08:50AM	What Makes Flux Power (FLUX) a Good Fit for 'Trend Investing' (Zacks) +6.07%
Oct-08-25 09:40AM	Is Flux Power (FLUX) Outperforming Other Computer and Technology Stocks This Year? (Zacks) +14.99%
Oct-06-25 08:50AM	Flux Power (FLUX) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks) +31.37%
Oct-03-25 08:26AM	Can Rising Electrolyzer Demand be a Catalyst for PLUG's Long-Term Growth? (Zacks)
Sep-29-25 12:00PM	Flux Power Holdings, Inc. (FLUX) is a Great Momentum Stock: Should You Buy? (Zacks) +17.63%
Sep-22-25 09:40AM	Is StoneCo (STNE) Outperforming Other Computer and Technology Stocks This Year? (Zacks) +17.05%
Sep-19-25 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Flux Power (FLUX) (Zacks)
Sep-17-25 03:01AM	Flux Power Holdings Inc (FLUX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -11.75%
Sep-16-25 05:15PM	Flux Power Holdings, Inc. (FLUX) Reports Break-Even Earnings for Q4 (Zacks) +52.17%
04:05PM	Flux Power Reports Fourth Quarter and Fiscal Year 2025 Financial Results (GlobeNewswire)
08:31AM	Flux Power Closes $5 Million Private Placement of Prefunded Warrants and Common Warrants (GlobeNewswire)
Sep-15-25 09:16AM	Earnings To Watch: Flux Power Holdings Inc (FLUX) Reports Q4 2025 Result (GuruFocus.com) +14.36%
Sep-09-25 08:31AM	Flux Power to Host Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call on September 16, 2025 (GlobeNewswire) +5.41%
Sep-04-25 08:31AM	Flux Power and Averest to Showcase Energy Management and Software Solutions for GSE at the International GSE Expo 2025 in Las Vegas (GlobeNewswire) -6.29%
Aug-29-25 11:05AM	Plug Power vs. Flux Power: Which Clean Energy Stock Has Greater Upside? (Zacks) -6.17%
Aug-27-25 10:31AM	Plug Power's Equipment Sales Rebound in Q2: What's Behind It? (Zacks)
Aug-25-25 04:05PM	Flux Power to Participate at Upcoming Financial Conferences (GlobeNewswire) -7.87%
Aug-21-25 12:09PM	Plug Power Cuts Costs to Lift Margins: Will the Results be Sustainable? (Zacks)
08:31AM	Flux Power Secures $1.2M+ Additional Order from Major North American Airline (GlobeNewswire)
Aug-13-25 12:57PM	Plug Power Targets $700M in Revenues in 2025: Can It Achieve the Goal? (Zacks)
Aug-07-25 05:31AM	Flux Power and Delta-Q Technologies to Host Joint Webinar: "Electrifying Warehouse & GSE Operations: A Guide to Lithium-Ion Transition" (GlobeNewswire)
Aug-05-25 08:31AM	Flux Power Awarded New Patent for Predictive Quantum Balancing (GlobeNewswire)
Jul-25-25 10:18AM	Plug Power's Equipment Weakness Grows: What's the Road Ahead? (Zacks) -6.63%
Jul-22-25 09:00AM	Flux Power Recognized Among Financial Times' Fastest Growing Companies in the Americas 2025 (GlobeNewswire)
Jul-01-25 08:33AM	Flux Power Secures a New $2M+ Purchase Order from Major N.A. Airline for G80 Lithium-Ion Battery Packs (GlobeNewswire) +8.61%
May-29-25 08:31AM	Flux Power to Present at the Maxim Group 2025 Virtual Tech Conference on Tuesday June 3, 2025 (Business Wire)
May-13-25 12:00PM	Fluxys Belgium: Regulated information - Payment of dividend (GlobeNewswire)
May-09-25 03:38AM	Flux Power Holdings Inc (FLUX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-08-25 05:25PM	Flux Power Holdings, Inc. (FLUX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Flux Power Reports Fiscal Year 2025 Third Quarter Financial Results (Business Wire)
May-07-25 11:45AM	Flux Power Holdings Inc (FLUX) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +7.91%
08:10AM	Rockwell Automation (ROK) Q2 Earnings and Revenues Beat Estimates (Zacks)
May-05-25 08:31AM	Flux Power Awarded Patent for an Intelligent Battery Cycle Life Maximization Algorithm, Pioneering the Future of AI-Driven Energy Optimization (Business Wire) +5.85%
Apr-24-25 08:31AM	Flux Power to Host Fiscal Third Quarter 2025 Results Conference Call on Thursday, May 8, 2025 at 4:30 p.m. Eastern Time (Business Wire)
Apr-21-25 08:31AM	Flux Power Launches New G96-G2 High Voltage Battery for Ground Support Equipment (Business Wire)
Apr-08-25 08:31AM	Flux Power Provides Update on Major Orders from Leading Airlines, Signaling Continued Industry-Wide Shift to Sustainable GSE Solutions (Business Wire)
Mar-21-25 12:06PM	Flux Power Holdings Inc (FLUX) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +20.00%
06:47AM	Q1 and Q2 2025 Flux Power Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 09:00PM	Flux Power Holdings, Inc. (FLUX) H1 2025 Earnings Call Transcript (SeekingAlpha)
04:01PM	Flux Power Reports Fiscal Year 2025 First and Second Quarter Financial Results (Business Wire)
Mar-12-25 08:31AM	Flux Power to Host Fiscal First and Second Quarter 2025 Results Conference Call on Thursday, March 20, 2025 at 4:30 p.m. Eastern Time (Business Wire)
Mar-11-25 08:31AM	Flux Power to Join the New Warehouse Podcast at ProMat 2025 to Discuss the Future of Telematics in Material Handling (Business Wire) +8.40%
Mar-10-25 08:31AM	Flux Power Appoints Veteran Technology Leader Krishna Vanka as Chief Executive Officer (Business Wire) -7.09%
Mar-06-25 08:31AM	Flux Power Receives First Purchase Order for Lithium-ion Battery Packs from Large U.S. Medical Supply Company (Business Wire) +10.74%
Mar-04-25 08:31AM	Flux Power to Exhibit at ProMat 2025 Tradeshow March 17-20 at McCormick Place in Chicago (Business Wire) -6.20%
Feb-25-25 04:05PM	Flux Power Receives Non-Compliance Notice from Nasdaq (Business Wire)
Feb-24-25 08:31AM	Flux Power CTO Paulus Geantil to Join Expert Panel at Future of Electrification Conference Hosted by Zapi Group (Business Wire) -6.54%
Feb-04-25 08:30AM	Flux Power price target lowered to $4 from $6 at Maxim (TipRanks)
Feb-01-25 08:45AM	Flux Power price target lowered to $6 from $10 at Lake Street (TipRanks)
Jan-29-25 05:49PM	Flux Power Reports Fiscal Full Year 2024 Financial Results (Business Wire)
Jan-07-25 08:31AM	Flux Power Appoints Kelly Frey as Chief Revenue Officer (Business Wire)
Nov-25-24 04:01PM	Flux Power Receives Non-Compliance Letter from Nasdaq (Business Wire)
Nov-21-24 04:01PM	Flux Power Announces Planned Retirement of Chairman and Chief Executive Officer Ron Dutt (Business Wire) +7.73% -13.08%
04:01PM	Flux Power Announces Planned Retirement of Chairman & Chief Executive Officer Ron Dutt (Business Wire)
Nov-15-24 04:05PM	Flux Power Provides Update on Inventory Restatement and Timeline to Report Fiscal FY 2024 and Q1 2025 Financial Results (Business Wire) -7.98% -5.48%
Oct-19-24 05:48PM	Flux Power Faces Nasdaq Compliance Challenges (TipRanks)
04:10PM	Flux Power receives non-compliance letter from Nasdaq (TipRanks)
Oct-18-24 04:05PM	Flux Power Receives Non-Compliance Letter from Nasdaq (Business Wire)
Sep-30-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Aviat and Flux and Encourages Investors to Contact the Firm (GlobeNewswire) -5.92%
Sep-12-24 08:31AM	Flux Power Announces Strategic Partnership with Leading Forklift OEM to Launch Private Label Battery Program (Business Wire) +11.22%
Sep-05-24 04:01PM	Flux Power to Write Down $1.7 Million in Obsolete Inventory, Requiring Restatement of Certain Previously Issued Financial Statements (Business Wire) -5.36%
Aug-21-24 08:31AM	Flux Power Expands Commitment to Sustainability with New Partnership for Lithium-ion Battery Recycling (Business Wire)
Jul-16-24 08:31AM	Flux Power Receives OEM-Approval for New L-Series L36-630840 Ah Battery Packs for Class 1 3-Wheel Counterbalance Forklifts (Business Wire)
Jul-09-24 08:31AM	Flux Power to Host Investor Tours at its Lithium-Ion Battery Pack Manufacturing Facility in Vista, California on Wednesday, August 7, 2024 (Business Wire)

Flux Power Holdings, Inc. engages in the design, development, and sale of rechargeable lithium-ion energy storage systems for industrial applications. It focuses on electric forklifts and airport ground support equipment. The company was founded by Christopher L. Anthony and Michael Johnson on September 21, 1998 and is headquartered in Vista, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mason Jeffrey Curtis	Vice President of Operations	Apr 01 '25	Sale	1.67	568	946	7,264	Apr 02 09:42 PM
DUTT RONALD F	Former CEO and President	Apr 01 '25	Sale	1.67	7,467	12,439	54,698	Apr 02 09:39 PM
DUTT RONALD F	Officer	Apr 01 '25	Proposed Sale	1.67	7,467	12,439		Apr 01 04:42 PM

KPRX

Kiora Pharmaceuticals Inc

FLUX

Flux Power Holdings inc

Upgrade your FINVIZ experience